PER-031-03已完成未知
RANDOMIZED, PHASE II, NON-COMPARATIVE, IRINOTECAN AND CARBOPLATINIAN TEST IN FRONT OF IRINOTECAN IN MINORS BETWEEN 1 AND 21 YEARS OF SOLID REFRACTORY TUMORS.
BRISTOL MYERS SQUIBB PERU S.A.,0 个研究点目标入组 0 人开始时间: 2003年4月28日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Completion of at least 6 cycles of therapy on BMS clinical protocol CA124-001 or CA124-002 and who continue to derive clinical benefit and are not experiencing intolerable toxicity from the therapy
- •Karnofsky score of at least 50 for subjects > 10 years of age; Lansky play scale of at least 50 for children 10 years of age and younger
- •Recovery to baseline or Grade 1 from toxicities (except alopecia or asthenia) resulting from previous therapies
- •Males and females, ages 1 - 21 years of age at the time of consent into CA124-001 or CA124-002
排除标准
- •A serious uncontrolled medical disorder that in the opinion of the Investigator would impair the ability of the subject to receive protocol therapy
- •Requirement to receive concurrent chemotherapy, immunotherapy, radiotherapy, or any other investigational drug while on study
- •Inadequate bone marrow and renal function
- •Concurrent receipt of Dilantin®(phenytoin), phenobarbital, primidone, Tegretol®(carbamazepine), Depacon®, Depakene®, Depakote®, and Deproic®(valproic acid)
研究者
相似试验
招募中
1 期
This is a phase 2 open label clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in subjects with recurrent ovarian cancerRecurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjectsMedDRA version: 21.1Level: PTClassification code: 10066697Term: Ovarian cancer recurrent Class: 100000004864CTIS2024-512138-13-00Adaptimmune LLC66
进行中（未招募）
1 期
Measurement of the effect of Empagliflozin versus Placebo in patients with end-stage renal disease(ESRD).EUCTR2016-002268-15-ITAZIENDA OSPEDALIERO-UNIVERSITARIA PISANA50
尚未招募
不适用
A PHASE 2, PARTIALLY-BLINDED, RANDOMIZED, COMPARATIVE STUDY OF THE EFFICACY OF DIFFERENT DOSES OF OXFENDAZOLE COMPARED TO A SINGLE DOSE OF ALBENDAZOLE FOR THE TREATMENT OF TRICHURIS TRICHIURA INFECTION IN ADULTS-B82 Unspecified intestinal parasitismUnspecified intestinal parasitismB82PER-083-20ASOCIACION BENEFICA PRISMA,
进行中（未招募）
1 期
Two arms trial with bevacizumab and fotemustine in patients with brain tumor previously treated.EUCTR2011-001363-46-ITROCHE
进行中（未招募）
不适用
A study of RO5024048 in combination with Telaprevir, Pegasys(Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients with ChronicHepatitis C Genotype 1 who were prior null responders to PegylatedInterferon/Ribavirin treatment.Chronic Hepatitis C (CHC), Genotype 1MedDRA version: 14.1Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-002715-28-ITROCHE140